Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 7 of 12
May 21, 2026The acquisition of Engage Bio highlights Eli Lilly's continued commitment to genetic medicine innovation by integrating novel delivery technologies aimed at enhancing therapeutic potential and patient outcomes.
Dr. Priya Nandakumar
May 20, 2026In utero gene therapy represents a novel frontier in genetic disease treatment, aiming to intervene at the earliest possible stage to prevent postnatal disease progression. The upcoming small-scale trial could pave the way for transformative approaches in precision medicine for rare genetic conditions.
Michael Torres
May 19, 2026Biotech firms, traditionally motors of scientific discovery and innovation, are increasingly constrained by market pressures stemming from Big Pharma's dominant business models. This growing tension threatens the sector's capacity to innovate. Structural reforms are essential to sustain and nurture biotech’s strategic innovation and maintain its role as a pioneer in biomedical advancements.
Dr. Priya Nandakumar
May 18, 2026Duracyte's innovative technology leverages engineered cells implanted in patients to produce biologic drugs directly, circumventing traditional manufacturing complexities and enabling real-time control by clinicians. This fusion of biotechnology and electronics heralds a potential shift in drug production and delivery paradigms.
Daniel Cho
May 14, 2026The FDA has granted approval to BeOne Therapeutics for Beqalzi, its novel therapy for mantle cell lymphoma patients who have experienced relapse or refractory disease. This approval introduces a new class of targeted therapy and represents an important milestone in blood cancer treatment modalities.
Daniel Cho
May 13, 2026The substantial investment in Isomorphic Labs highlights growing confidence in AI-driven biotechnology research, diverging from traditional investment patterns that favor more developed assets with clinical data.
Sophia Reynolds
May 12, 2026Gene therapy holds transformative potential for treating complex diseases, but safety concerns remain paramount. Capsida's recent silence regarding the specific brain receptor targeted in its halted trial has frustrated the field and underscores the need for transparency in investigating adverse outcomes linked to novel therapies.
Emily Carter
May 5, 2026The development represents a significant step in combining RNA-based therapeutics with a multi-faceted approach to treating complex liver diseases. Madrigal’s strategy to integrate multiple genetic medicines could transform treatment paradigms for MASH and other metabolic liver disorders, underscoring innovation at the intersection of biotechnology and precision medicine.
Daniel Cho
May 5, 2026Johnson & Johnson’s latest therapy for IBD patients did not meet all statistical benchmarks in recent trials but continues to represent a potential advancement in the treatment landscape. This blog explores the implications of these trial results and what they mean for the future of IBD therapies.
Sophia Reynolds
Apr 30, 2026J. Craig Venter's contributions to the field of genomics and biotechnology have left an indelible mark on modern science. As the architect of the first human genome sequencing and a relentless innovator, his career spanned decades of revolutionary scientific developments. This article dives deep into his life, scientific impact, and the nuanced legacy that continues to influence biotech today.
Sophia Reynolds
Apr 29, 2026The departure of seasoned scientists and inspectors from the USDA is raising alarms in the food safety community. The implications are broad, touching everything from regulatory oversight to public health assurances. This post delves into the causes, consequences, and potential mitigations of this emerging crisis.
Jonathan Blake
Apr 29, 2026The phase 3 comparison underscores the competitive landscape in obesity therapeutics, highlighting advancements in molecular targets and clinical outcomes. With obesity being a growing global health challenge, these developments are critical for expanding effective treatment options.
Dr. Alex MorganMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.